ORIGINAL RESEARCH article
Front. Neurol.
Sec. Headache and Neurogenic Pain
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1570447
Efficacy of Single vs. Multiple Botulinum Toxin Type A Injections for Trigeminal Neuralgia
Provisionally accepted
- Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The effectiveness of Botulinum toxin type A (BTX-A) has been established in trigeminal neuralgia (TN). This study aimed to assess the therapeutic efficacy and safety of BTX-A injection within a group of TN patients who have chosen to continue BTX-A therapy. Methods: This was a retrospective medical record–review study. Demographic and clinical features and severity and frequency of pain before and 4 weeks after the BTX-A administration were extracted from the patient files. BTX-A was injected into the painful area subcutaneously and/or submucosally. BTX-A injections were performed by the same physician using the same methods. Pain severity was assessed using the visual analog scale (VAS). The patient’s overall response to treatment was assessed using the Patient Global Impression of Change (PGIC). Patients were divided into two groups, single-treatment (TN-S) group and multiple-treatment (TN-M) group, according to the numbers of treatment. Results: Thirty patients were included in this study. We classified 16 (53.33%) as TN-S group and 14 (46.67%) as TN-M group. The median VAS score of all patients was 8 (6.75, 10) before the first treatment and 3 (2, 6.25) after the first treatment (P < 0.001). In the TN-M group, median of the difference of VAS before and after treatment of the first and the last treatment were 7 (5, 8) and 5 (2, 7.25) respectively, indicating a significantly better effect for the first treatment compared with the last treatment (P = 0.024). However, this difference in PGIC distributions between the two treatments was not significant (P = 0.070). Conclusions: In summary, BTX-A treatment was effective in TN. Elderly patients and patients with good response to the first treatment were more likely to choose to continue BTX-A multiple-treatments. BTX‐A remains effective within a group of TN patients who have chosen to continue BTX-A therapy, but the efficacy decreases to a certain extent after multiple treatments.
Keywords: Botulinum toxin type A, Trigeminal Neuralgia, Repeated injection, Multiple treatments, efficacy evaluation
Received: 03 Feb 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Xu, Guo, Chen, Bao, Li, Ma, Zhang, Liu and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jing Liu, Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
Wei-Feng Luo, Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.